Phragma Therapeutics is dedicated to advancing treatments for neurological and neurodegenerative diseases through innovative strategies to restore blood-brain barrier (BBB) integrity. Focused on conditions like Alzheimer’s and Parkinson’s, we develop targeted therapies to strengthen CNS barriers.
Our subsidiary, Thera Phragma in Greece, extends our research efforts, driving global impact with local expertise.
"Phragma" derives from the Greek word "φραγμός", signifying "barrier," reflecting our mission at Phragma to address barriers in both the brain and broader scientific challenges.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Boston, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://phragmatx.com
- Keywords
- Thera Phragma.
- HQ
- Boston
Phragma Therapeutics Questions
Phragma Therapeutics's website is https://phragmatx.com
Phragma Therapeutics's LinkedIn profile is https://www.linkedin.com/company/phragma-therapeutics
Phragma Therapeutics has
6 employees.
View email and phone details for 6
employees at Phragma Therapeutics.
Phragma Therapeutics's industry is
Biotechnology Research
Phragma Therapeutics's top competitors are
Neurify Biosciences,
Thera Phragma,
Lipocine Inc.,
Alchemab Therapeutics Ltd,
Neuphoria Therapeutics Inc,
Encephalos Life Sciences Llc,
Vigil Neuroscience,
Ebvio,
Flatiron Bio,
Therapharma.
Phragma Therapeutics's categories are Biotechnology Research
Phragma Therapeutics's founding year is 2023
